Eli Lilly (NYSE: LLY) is a leader in the global pharmaceutical sector with a drug and medicine cabinet spanning everything from diabetes and depression, to obesity and Alzheimer’s. The rapid success of its GLP-1 weight loss drug, Mounjaro and its obesity pipeline has caught the attention of investors around the world.
If you’re thinking about buying Eli Lilly shares, remember that drug approvals can be unpredictable. However, Eli Lilly’s strong R&D pipeline, along with its market positioning and pricing power could make it a long-term healthcare growth stock.
How to buy shares in Eli Lilly and Company
Open a brokerage account.Choose from our top broker picks or compare brokers in depth. To trade US shares you'll need to complete a W8-BEN form – typically part of the sign-up process.
Fund your account.Add money to your account via bank transfer or debit card.
Search the platform by ticker symbol.LLY in this case.
Choose an order type.Place a market order (or limit order, if you want to try to hold out for a specific price) with your preferred number of shares or investment amount.
Submit the order.It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.
Our top picks for where to buy Eli Lilly and Company shares
We analysed all popular share dealing platforms in the UK using 35 data points and combined this with our expert insight from using the apps. The platforms we've selected as best for each category offer stand-out features or a unique combination of elements for a specific aspect of investing. If we show a "Promoted for" pick, it's been chosen from among our partners and is based on factors that include special features or offers, and the commission we receive. Keep in mind that our picks may not always be the best for you – it's important to compare for yourself. More details in our full methodology.
Eli Lilly and Company stock chart
Use our graph to track the performance of LLY stock over time.
We currently don't have that product, but here are others to consider:
How we picked these
Finder Score for trading platforms
To make comparing even easier we came up with the Finder Score. Costs, features, ease and range of investments across 30+ platforms are all weighted and scaled to produce a score out of 10. The higher the score the better the platform – simple.
These providers cover a wide range of stocks, but we can't guarantee they'll all offer this stock.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Boost your investment IQ!
Subscribe now for market insights, expert advice and a chance to win £400! (T&Cs)
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Historical closes compared with the last close of $974.96
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Eli Lilly and Company P/E ratio, PEG ratio and EBITDA.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Eli Lilly and Company's shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of March 2025 (25.37). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Eli Lilly and Company's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3948. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Eli Lilly and Company's PEG ratio in relation to those of similar companies.
Forward annual dividend yield: 0.7% of stock value
Dividend payout ratio: 21.96% of net profits
Eli Lilly and Company has recently paid out dividends equivalent to 0.63% of its share value annually.
Eli Lilly and Company has paid out, on average, around 21.96% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.7% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 0.7% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about 6.23 per share.
While Eli Lilly and Company's payout ratio might seem low, this can signify that the company is investing more in its future growth.
Eli Lilly and Company's next dividend payout is expected around 9 June 2026. To benefit from it's next dividend payout, you'll need to buy Eli Lilly and Company shares before 14 May 2026 (the "ex-dividend date").
Eli Lilly and Company's dividend yield is perhaps best considered in relation to those of similar companies.
Eli Lilly and Company's fiscal year ends in December.
Eli Lilly and Company's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
It's as easy to sell Eli Lilly and Company as it is to buy! Here's how to sell Eli Lilly and Company shares that you already own.
Open your investment app. If you've got one with desktop access, you can log in online
Go to your portfolio. This should be in the main menu
Find your shares. You may be able to search your portfolio
Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
Sell your Eli Lilly and Company shares. Your investment platform will let you know when your shares are sold
Most dealing providers will let you use your debit card to top up your account and buy shares. The main ways are with a debit card, bank transfer or with Apple/Google Pay.
The easiest way to get hold of some Eli Lilly and Company shares is to sign up for a share trading app and place a market order or basic order. This type of order tells the platform that you're interested, so it'll try to execute it as quickly as it can. It could take some time for the order to go through, especially if there's a lot of volatility in Eli Lilly and Company shares.
Yes. When you investing in a US stock, you need to complete a W8-BEN form to minimise your tax liability. Whether these are automatically handled for you depends on your broker, so it would be a good idea to check with them directly.
George is a deputy editor at Finder. He has previously written for The Motley Fool UK, Nasdaq, Freetrade, Investing in the Web, MoneyMagpie, Online Mortgage Advisor, Wealth, and Compare Forex Brokers.
He's focused on making personal finance and investing engaging for everyone. To do this he draws from previous work and his Level 4 Diploma for Financial Advisers (DipFA), sharing what he’s learnt. When he’s not geeking out about money, you’ll find him playing sports and staying active.
See full bio
George's expertise
George
has written
278
Finder guides across topics including:
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
Ever wondered how to buy shares in Walgreens? We explain how and compare a range of providers that can give you access to many brands, including Walgreens.
Ever wondered how to buy shares in Medtronic? We explain how and compare a range of providers that can give you access to many brands, including Medtronic.
Ever wondered how to buy shares in AstraZeneca? We explain how and compare a range of providers that can give you access to many brands, including AstraZeneca.
Learn more about GSK’s recent performance and where you can buy GSK shares. We also run through a helpful checklist for anyone looking to invest.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Ready to compare platforms?